Talis Biomedical regains compliance with Nasdaq minimum bid price requirement

Talis Biomedical announced that it received written notice from The Nasdaq Stock Market dated July 20, 2023, that the Company has regained compliance with the minimum bid price requirement of at least $1.00 per share under Nasdaq Listing Rule 5550(a)(2). In order to regain compliance, the Company’s common stock was required to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days which the Company satisfied on July 19, 2023. Accordingly, the Notice stated that Nasdaq now considers the matter closed. The Notice follows the Company’s 1-for-15 reverse stock split approved by stockholders on June 9, 2023, and effected at 5:00 p.m. Eastern time on July 5, 2023, after which the Company’s common stock closed at a minimum of $1.00 per share for the 10 consecutive business days ended July 19, 2023.